NXC 736
Alternative Names: NXC-736; NXC-736 - NextGen BioscienceLatest Information Update: 28 Nov 2024
At a glance
- Originator NextGen Bioscience
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alopecia areata
- Phase I Ulcerative colitis
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in South Korea (PO)
- 01 Sep 2024 Phase-II clinical trials in Alopecia areata (Monotherapy) in South Korea (PO) (NCT06104839)
- 01 Nov 2023 NEXTGEN Bioscience plans a phase IIa trial for Alopecia areata (Monotherapy) (PO) in April 2024 (NCT06104839)